🇺🇸 FDA
Pipeline program

VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection., ADVATE 500 IU powder and solvent for solution for injection.

071102

Phase 3 small_molecule active

Quick answer

VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection., ADVATE 500 IU powder and solvent for solution for injection. for Hereditary severe von Willebrand Disease in children is a Phase 3 program (small_molecule) at Baxalta Innovations GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Baxalta Innovations GmbH
Indication
Hereditary severe von Willebrand Disease in children
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials